ArticleJournal of controlled release : official journal of the Controlled Release Society2019
Tumor-specific macrophage targeting through recognition of retinoid X receptor beta.
Article in Journal of controlled release : official journal of the Controlled Release Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 47 citations in OpenAlex.
- Biomimetic proteolipid vesicles delivering small activating RNA to activate the macrophage immunotherapy for the treatment of lung cancer.Journal of nanobiotechnology · 2026Article
- Alterations in Adipocytokine Signaling Pathway and Pyroptosis in Neonatal Hypoxic-ischemic Encephalopathy.Current medicinal chemistry · 2025Article
- Peptide targeting improves the delivery and therapeutic index of glucocorticoids to treat rheumatoid arthritis.Journal of controlled release : official journal of the Controlled Release Society · 2024Article
- Advances in targeted delivery of mRNA into immune cells for enhanced cancer therapy.Theranostics · 2024Review
- Review
- Tumor-Associated Macrophage Subsets: Shaping Polarization and Targeting.International journal of molecular sciences · 2023Review
- Peptide-guided delivery improves the therapeutic efficacy and safety of glucocorticoid drugs for treating acute lung injury.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Article
- "Two birds with one stone" strategy for the lung cancer therapy with bioinspired AIE aggregates.Journal of nanobiotechnology · 2023Article
- Macrophages as potential targets in gene therapy for cancer treatment.Exploration of targeted anti-tumor therapy · 2023Review
- Cell Membrane-Camouflaged Nanoparticles Mediated Nucleic Acids Delivery.International journal of nanomedicine · 2023Review
- Peptide-assembled nanoparticles targeting tumor cells and tumor microenvironment for cancer therapy.Frontiers in chemistry · 2023Review
- Advancements in Macrophage-Targeted Drug Delivery for Effective Disease Management.International journal of nanomedicine · 2023Review
- Versatile Nano-PROTAC-Induced Epigenetic Reader Degradation for Efficient Lung Cancer Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- Microbiome as an immune regulator in health, disease, and therapeutics.Advanced drug delivery reviews · 2022Review
- Molecular ZIP codes in targeted drug delivery.Proceedings of the National Academy of Sciences of the United States of America · 2022Review
- Nanocarriers Used in Drug Delivery to Enhance Immune System in Cancer Therapy.Pharmaceutics · 2021Review
- Transportan Peptide Stimulates the Nanomaterial Internalization into Mammalian Cells in the Bystander Manner through Macropinocytosis.Pharmaceutics · 2021Article
- Fusogenic porous silicon nanoparticles as a broad-spectrum immunotherapy against bacterial infections.Nanoscale horizons · 2021Article
- Tumor Associated Macrophages: Origin, Recruitment, Phenotypic Diversity, and Targeting.Frontiers in oncology · 2021Review
- 20(S)-Protopanaxadiol inhibits epithelial-mesenchymal transition by promoting retinoid X receptor alpha in human colorectal carcinoma cells.Journal of cellular and molecular medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 3 countries.
Funding
Abstract
Macrophages play important and diverse roles during cancer progression. However, cancer therapies based on macrophage modulation are lacking in tools that can recognize and deliver therapeutic payloads to macrophages in a tumor-specific manner. As a result, treatments tend to interfere with normal macrophage functions in healthy organs. We previously identified a macrophage-binding peptide, termed CRV. Here, we show that upon systemic administration into tumor-bearing mice, CRV selectively homes to tumors, extravasates, and preferentially binds to macrophages within. CRV exhibits a higher affinity for tumor macrophages than for other cells in tumors or for other macrophage types elsewhere in the body. We further identified and validated retinoid X receptor beta (RXRB) as the CRV receptor. Intriguingly, although it is known as a nuclear receptor, RXRB shows a prominent cell surface localization that is largely restricted to tumor macrophages. Systemic administration of anti-RXRB antibodies also results in tumor-selective binding to macrophages similar to CRV. Lastly, we demonstrate the ability of CRV to improve the delivery of nano-carriers into solid tumors and macrophages within. In summary, we describe here a novel cell surface marker and targeting tools for tumor macrophages that may aid in future development of macrophage-modulatory cancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.